CN EN

news

Congratulations to TaiGen for Anti-Influenza Drug TG-1000 Approved for Clinical Trial

TaiGen's TG-1000 anti-influenza drug and capsules (CXHL2000100, CXHL2000099) secure CDE IND approval from China's NMPA for adult influenza A and B clinical trials.
June 04, 2020

Congratulations to Fosun Pharma for Selective BCL-2 Inhibitor FCN-338 Accepted for Clinical Trial

Fochon Pharmaceuticals' FCN-338, a selective BCL-2 inhibitor, has been accepted by China's CDE and FDA for clinical trials, targeting hematological malignancies.
May 28, 2020

New Preclinical Models for NASH Provide Strong Clinical Relevance and Shortened Timelines

SAN DIEGO, May 26, 2020 – BioDuro, LLC, a leading drug discovery and development services organization, announced today the availability of two new preclinical models for Non-alcoholicsteatohepatitis
May 26, 2020

BioDuro & Silexon Form Strategic Collaboration to Develop New Anti-Cancer Drugs

SAN DIEGO, May 26, 2020 – BioDuro, LLC, a leading drug discovery and development services organization, announced today the availability of two new preclinical models for Non-alcoholicsteatohepatitis
May 26, 2020

BioDuro & neoX Partner to Create Next Generation Antibody Discovery Platform

SAN DIEGO and BEIJING, April 28, 2020 – BioDuro, LLC, a leading drug discovery and development services organization, and neoX, a leading-edge artificial intelligence and biophysics focused biotech, ann
April 28, 2020
Total 84 12...6789101112...1617
0.186417s
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all